Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Navitoclax + TAK-901 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Navitoclax | ABT-263 | BCL-XL inhibitor 14 BCL2 inhibitor 29 | Navitoclax (ABT-263) is a BCL2, BCL-XL, and BCL-W inhibitor, which may enhance the efficacy of chemotherapeutics (PMID: 25787766, PMID: 32513939). | |
| TAK-901 | Aurkb Inhibitors 21 FGFR2 Inhibitor 24 FLT3 Inhibitor 69 | TAK-901 is a selective inhibitor of Aurora B kinase, FLT3, and FGFR2, and has demonstrated anti-tumor activity in several cancer models (PMID: 23358665, PMID: 28179288). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|